Although previous in vivo studies have shown that both compounds induce thrombocytopenia due to their ability to inhibit BCL‐xL, various clinical trials are currently ongoing (e.g., NCT04041050, NCT00788684, NCT02079740, NCT03181126, and NCT00481091) for both hematopoietic and solid tumors to evaluate the efficacy of ABT‐263/navitoclax (used at appropriate doses to avoid thrombocytopenia) in combination with various drugs. The gene discussed is BCL2L1; the disease is Thrombocytopenia.